# US 2024/0197692 A1 · Combination Comprising Everolimus and Amcenestrant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197692 A1
- Document ID: US20240197692A1
- Status: Published application
- Kind: A1
- Application number: 18/286,496
- Filed: 2022-04-12
- Published: 2024-06-20
- Earliest claimed: 2021-04-12
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Monsif Bouaboula; Fangxian Sun
- Web page: https://patentgrep.com/patent/US20240197692A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61P 35/04: specific for metastasis
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Herein are provided a combination of everolimus and of amcenestrant or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A combination comprising amcenestrant or a pharmaceutically acceptable salt thereof, and everolimus.

### Claim 19 (depends on 18)

The combination according to claim 18, wherein the combination shows therapeutic synergy.

### Claim 20

A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of everolimus.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the cancer is breast cancer.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the amcenestrant or a pharmaceutically acceptable salt thereof, and the everolimus are administered separately, either simultaneously or sequentially.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the amcenestrant or a pharmaceutically acceptable salt thereof, is administered simultaneously with everolimus.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the amcenestrant or a pharmaceutically acceptable salt thereof, is administered sequentially with everolimus.

### Claim 25

A pharmaceutical composition comprising amcenestrant or a pharmaceutically acceptable salt thereof, everolimus, and at least one pharmaceutically acceptable excipient.

### Claim 26 (depends on 25)

A method of treating cancer comprising administering to a patient in need thereof the pharmaceutical composition according to claim 25.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the cancer is breast cancer.

### Claim 28

A method of treating cancer in a patient who is being treated with amcenestrant or a pharmaceutically acceptable salt thereof, comprising administering to the patient an effective amount of everolimus.

### Claim 29

A method of treating cancer in a patient on stable treatment with amcenestrant or a pharmaceutically acceptable salt thereof, comprising administering to the patient a therapeutically effective amount of everolimus.

### Claim 30

A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of everolimus, wherein the patient is also being treated with amcenestrant or a pharmaceutically acceptable salt thereof.

### Claim 31

A kit comprising:
a first pharmaceutical composition comprising amcenestrant or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;
a second pharmaceutical composition comprising everolimus and at least one pharmaceutically acceptable excipient;
wherein the first pharmaceutical composition and the second pharmaceutical composition are in separate compartments.

### Claim 32 (depends on 31)

The kit of claim 31, further comprising a package insert indicating that the first and second pharmaceutical compositions are administered for the treatment of cancer.

### Claim 33 (depends on 31)

The kit of claim 31, wherein the cancer is breast cancer.

### Claim 34 (depends on 31)

The kit of claim 31, further comprising a package insert indicating that the first and second pharmaceutical compositions are administered simultaneously or sequentially with respect to each other.

### Claim 35 (depends on 31)

The kit of claim 31, further comprising a package insert indicating that the first and second pharmaceutical compositions are administered simultaneously with respect to each other.

### Claim 36 (depends on 31)

The kit of claim 31, further comprising a package insert indicating that the first and second pharmaceutical compositions are administered sequentially with respect to each other.
